Evaluation of randomization and blinding
low bowel, Prostate Cancer, GI, gastrointestinal; GU, genitourinary, Prostate, prostate cancer
DISEASE, PROSTATE CANCER, PROSTATE CANCER, PROSTATE
This study will employ a randomized phase II non-inferiority design to compare 5 fractions of ultra-fractionated MRgRT versus 20 fractions of moderately hypofractionated MRgRT in the salvage setting for prostate cancer patients after prostatectomy. Patients will be stratified according to baseline EPIC bowel and urinary domain scores (Trial Schema. Expanded Prostate Cancer Index Composite (EPIC), EuroQol-5D index (EQ-5D) and International Prostate Symptom Score (IPSS) quality of life (QoL) surveys are collected at baseline, end of salvage radiotherapy, and at 3 month, 6 month, 12 month and 60 month follow up. GI, gastrointestinal; GU, genitourinary; RT, salvage radiotherapy. *EPIC score groups defined as: high bowel score > 96, low bowel score ≤ 96, high urinary score > 84, low urinary score ≤ 84. **Patients with PSA > 0.4 ng/mL, high-risk Decipher genomic classifier scores, or pathologically node positive disease will receive pelvic nodal radiotherapy and androgen deprivation therapy (ADT) as per the clinician’s discretion